AI-ready NAM data is now the regulatory bottleneck

The regulator is becoming a data system

On 6 May 2026, FDA announced that Elsa 4.0 now sits on HALO, a consolidated platform spanning more than forty application and submission data sources, systems, and portals [1]. The important shift is architectural. Review work is moving from isolated documents toward AI-assisted access across structured regulatory data [1]. That does not make PDF dossiers disappear overnight, but it changes what a high-quality evidence package looks like.

For NAMs, this matters more than for traditional animal toxicology. FDA has encouraged NAM data in drug submissions where scientifically justified [2]. NAM data is newer, more heterogeneous, and often vendor-shaped: organoids, microphysiological systems, PBPK models, QSAR workflows, omics readouts, image-derived endpoints, and lab-specific acceptance criteria [2][6]. The risk is not that regulators reject NAMs because they are modern. The risk is that the data arrives in a form that cannot be compared, audited, or reused.

FAIR is necessary, but not enough for AI

The FAIR principles were explicitly designed for machine-actionable data: data and metadata should be findable, accessible, interoperable, and reusable by computational systems as well as by people [3]. That foundation is still essential. A NAM dataset without persistent identifiers, controlled vocabularies, provenance, and clear reuse conditions is difficult to inspect and almost impossible to aggregate responsibly [3].

AI-readiness adds stricter expectations. Bridge2AI frames AI-ready biomedical data around FAIRness plus provenance, characterization, explainability, sustainability, computability, and documentation of ethical data practice [4]. In practice, that means a dataset can be FAIR-ish and still unsuitable for model training or regulatory AI-assisted review. If assay labels are inconsistent, donor provenance is vague, protocol changes are undocumented, or endpoint definitions shift between sites, the model may process the files but the evidence remains weak.

NAM value depends on the data layer

The scientific case for some NAMs is strong in defined contexts of use. The human Liver-Chip study by Ewart and colleagues reported 87% sensitivity and 100% specificity across a blinded set of 27 drugs for drug-induced liver injury prediction, with an estimated productivity gain exceeding 3 billion USD per year if adopted broadly in preclinical small-molecule workflows [5]. That is exactly the kind of result that can justify platform investment.

But the ROI is conditional. A Liver-Chip result only becomes a durable asset if the output can be joined to test article identity, exposure conditions, donor and cell metadata, device parameters, controls, acceptance criteria, raw and processed endpoints, analysis scripts, and downstream safety claims. Otherwise the experiment may help one project team make one decision, while failing to strengthen the sponsor's reusable evidence base. The same logic applies to organoids and other MPS platforms: without harmonized protocols and metadata, platform reuse is a promise rather than an asset [6][7].

What sponsors should build now

The practical response is not to wait for every standard to settle. It is to make NAM data first-class in the internal data architecture. Each NAM study should have a context-of-use record, a structured metadata schema, a validation evidence matrix, and a traceable link from raw result to regulatory claim. Vendor outputs should be accepted only when they can export stable identifiers, documented metadata, and machine-readable results [3][4].

Two current efforts are useful anchors. NAMO provides an ontology-backed framework for describing organoids, organ-on-chip systems, computational models, and validation concordance [6]. The Pistoia Alliance In Vitro NAM Data Standards project is working on assay performance metrics, method ontology, metadata annotation, and best practices for data management and analysis [7]. These are not cosmetic standards efforts. In Neuronautix's view, they define whether NAM data can survive contact with AI-assisted review, cross-study comparison, and later reuse in model development.

The conclusion is deliberately conservative: NAMs are not regulatory evidence because they are novel, human-based, or animal-sparing. They become regulatory evidence when their context, biology, technical performance, uncertainty, and provenance are recorded in a form that a reviewer, a warehouse, and an AI system can interrogate [2][3][4].